Lancet paper on HCQ slammed by scientists

▴ Lancet paper on HCQ slammed by scientists
Scientific community is miffed about the quality and lack of research in Lancet HCQ paper

More than 100 scientists and clinicians have sent an open letter to The Lancet's editor, Richard Horton, and the paper's authors asking them many uncomfortable questions, but have failed to receive convincing answers from the authors. How can a drug like Hydroxychloroquine produced in such huge quantities for a country as populous as India, safely consumed by millions & millions of chronic users for so many decades without any adverse effects, suddenly get a negative report in 2020 when it's most needed for a pandemic such as COVID -19

A study of 96,000 hospitalized coronavirus patients
Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis published in The Lancet found that those who received hydroxychloroquine (HCQ) had a significantly higher risk of death compared with those who did not. The study concluded that individuals treated with HCQ (or the closely related drug chloroquine) were also more prone to develop arrhythmia, that can lead to sudden cardiac death.
After the publication of this controversial article, the World Health Organisation's (WHO) advisory suspended the use of hydroxychloroquine (HCQ) in COVID-19 patients. This came as a big shock to India, the second most populated country in the world, where HCQ is produced in large quantities to meet the demand of treating a large number of Malaria patients. The disappointment was huge because The Lancet study showed distinct harm, apart from no real benefit to the COVID- 19 patients. A negative report against HCQ in times when the drug is needed all over the globe urgently appeared unbelievable to the Indian health authorities who have witnessed the long use of HCQ, safely consumed by millions & millions of Indians without any adverse effects for so many decades.

Indian authorities quickly swung into action. First, it was the Union Health Ministry of India that expressed reservations about the WHO's advisory to suspend the use of HCQ in COVID-19 patients. Now, it's the Indian Council of Medical Research (ICMR) that has written to the WHO citing the differences they have found in dosage standards between Indian and international trials. This is a significant finding that could explain the HCQ efficacy issues in treating COVID-19 patients.

Currently, the Indian protocols to treat severe coronavirus patients in ICU, recommend a 5- day course. First, a heavy dose of 400mg HCQ (morning & night) on the first day, followed by 200 mg HCQ (morning & night) for the next four days. The total dosage of 2400 mg administered to a patient in 5 days.

Indian officials disagreeing with the WHO's advisory believe that the dosage levels given in the international trials are massive- 800 mg x 2 loading doses 6 hours apart followed by 400 mg x 2 doses per day for 10 days. This makes the total dosage - 9600 mg given over 11 days -about four times higher than the one given in Indian patients.

ICMR officials have found their low dose HCQ protocol to be efficacious enough that has helped the COVID- 19 patients in India to recover quickly. They are of the opinion that there was no reason for the WHO to suspend the trial for safety concern.

The hydroxychloroquine (HCQ) efficacy issue has generated a lot of debate globally as well. The Lancet study is now under severe criticism from more than 180 scientists worldwide for not releasing the data for an independent analysis outside.

The scientific community is furious seeing a poorly written and poorly executed study published in The Lancet that has not only received huge underserved publicity but also created a massive negative impact on the other judiciously planned clinical trials being conducted around the world. More than 100 scientists and clinicians have sent an open letter to The Lancet's editor, Richard Horton, and the paper's authors asking them many uncomfortable questions, but have failed to receive convincing answers from the authors.

Story Source; in.dental-tribune.com

Tags : #Lancet #ICMR #HCQ #Scientists

About the Author


Team Medicircle

Related Stories

Loading Please wait...
-Advertisements-


Trending Now

Lawsuits over COVID infections could be costly for US employersSeptember 28, 2020
WHO work with migrant camps in Greece September 28, 2020
Now Quali55care aggregates medical equipment just like Zomato and Swiggy aggregates restaurants, says Harddik PatelSeptember 28, 2020
Global Coronavirus deaths cross 1 Million markSeptember 28, 2020
Global Coronavirus deaths cross 1 Million markSeptember 28, 2020
Global Coronavirus deaths cross 1 Million markSeptember 28, 2020
Navigation system and Robotics amongst the new trends in spine surgery says Dr. G Amrit, Orthopedic Spine Surgeon  September 28, 2020
WISI Meetings: Sports Management (India)September 28, 2020
Indoco Remedies launches FEVINDO : 400 mg FavipiravirSeptember 28, 2020
Myanmar extends COVID-19 lockdown in 11 new areas ; International flights suspended till Oct 31September 28, 2020
Nagaland, Manipur Covid-19 News Update Sep 28, 2020September 28, 2020
Delhi reports 3,292 fresh cases of COVID-19 , Himachal Pradesh 195September 28, 2020
9543 people test positive for new Covid-19 cases in KarnatakaSeptember 28, 2020
Zymo Research granted CE IVD Mark for sample collection devicesSeptember 28, 2020
India COVID-19 News update Date across States and UT's - September 27 , 2020September 27, 2020
VAXART investigation initiated by former Louisiana Attorney GeneralSeptember 26, 2020
Bangladesh prepares for ‘second wave’ as Corona death crosses 5,000 markSeptember 26, 2020
Thane district in Maharashtra recorded 1,671 new cases of COVID-19September 26, 2020
NPPA decides to cap price of liquid medical oxygen & medical oxygen cylindersSeptember 26, 2020
Mesothelioma September 26, 2020